Flurifen

Form: Tablets
Dosage: 100mg
Packaging: 15 film-coated tablets

Active substance :   flurbiprofen

Form : Film coated tablet

Dosage :    100 mg of flurbiprofen per tablet

Packaging :  Box with 15 tablets

Target : Adults and  children as from 12 y

Flurifen is indicated for

  • Analgesic effect in the relief of mild to moderate pain in conditions such as
    • dysmenorrhoea (painful menstruation)
    • dental pain
    • post-operative pain
    • migraine
  • Treatment of the symptoms of trauma such as periarthritis, frozen shoulder,bursitis, tendinitis, tenosynovitis, low back pain, sprains and strains
  • Treatment of rheumatoid disease, osteoarthritis, ankylosing spondylitis, musculoskeletal disorders,

The recommended daily dose in adults (> 12 years) is 150 to 200 mg per day, in two, three or four divided doses.

In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dosage may be increased to 300 mg in divided doses.

For dysmenorrhoea, a dosage of 100 mg may be administered at the start of symptoms followed by 50 or 100 mg given at four- to six-hour intervals. The maximum total daily dosage should not exceed 300 mg.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma